Morgan Stanley Maintains Overweight on BeOne Medicines, Raises Price Target to $476
Benzinga Newsdesk 6 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Morgan Stanley analyst Sean Laaman maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $465 to $476.
Morgan Stanley analyst Sean Laaman maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $465 to $476.
